New internal U.S. Food and Drug Administration (FDA) research reports obtained by The New York Times have recommended the type 2 diabetes drug Avandia (rosiglitazone) be pulled from the market. The confidential reports state that if everyone taking Avandia for diabetes were switched to a similar type 2 diabetes medication, there would be about 500 fewer heart attacks and 300 fewer heart failures each month. Avandia was linked to over 100 deaths a month in 2009.
The final conclusion by doctors one of the obtained reports was that Avandia should be removed from the market. According to the news article, an internal debate is raging at the FDA on how to handle the Avandia question. Avandia was nearly pulled off the market in 2007, but remained on the market after a razor-thin vote by an FDA oversight board. GlaxoSmithKline, the manufacturer of Avandia, has been on the defensive. A report from the U.S. Senate accuses GlaxoSmithKline of trying to intimidate doctors and misrepresent negative data associated with Avandia.
If you or a loved one has suffered a heart-related injury while taking Avandia for type 2 diabetes, you may be entitled to compensation. Contact The Law Offices of Larry H. Parker at (800) 333-0000 today for a free consultation. For more information on Avandia, visit our Avandia Information page. For more information on the FDA’s findings, find The New York Times news article here. The just released FDA Safety Communication on Avandia can be found here.
Avandia® is a registered trademark of GlaxoSmithKline.
